Cargando…
A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study
Chronic obstructive pulmonary disease (COPD) is an inflammatory lung condition, causing progressive decline in lung function leading to premature death. Acute exacerbations in COPD patients are predominantly associated with respiratory viruses. Ribavirin is a generic broad-spectrum antiviral agent t...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179635/ https://www.ncbi.nlm.nih.gov/pubmed/32071044 http://dx.doi.org/10.1128/AAC.02267-19 |
_version_ | 1783525679160098816 |
---|---|
author | Dumont, Etienne F. Oliver, Amanda J. Ioannou, Chris Billiard, Julia Dennison, Jeremy van den Berg, Frans Yang, Shuying Chandrasekaran, Vijayalakshmi Young, Graeme C. Lahiry, Anirban Starbuck, David C. Harrell, Andrew W. Georgiou, Alex Hopchet, Nathalie Gillies, Andy Baker, Stephen J. |
author_facet | Dumont, Etienne F. Oliver, Amanda J. Ioannou, Chris Billiard, Julia Dennison, Jeremy van den Berg, Frans Yang, Shuying Chandrasekaran, Vijayalakshmi Young, Graeme C. Lahiry, Anirban Starbuck, David C. Harrell, Andrew W. Georgiou, Alex Hopchet, Nathalie Gillies, Andy Baker, Stephen J. |
author_sort | Dumont, Etienne F. |
collection | PubMed |
description | Chronic obstructive pulmonary disease (COPD) is an inflammatory lung condition, causing progressive decline in lung function leading to premature death. Acute exacerbations in COPD patients are predominantly associated with respiratory viruses. Ribavirin is a generic broad-spectrum antiviral agent that could be used for treatment of viral respiratory infections in COPD. Using the Particle Replication In Nonwetting Templates (PRINT) technology, which produces dry-powder particles of uniform shape and size, two new inhaled formulations of ribavirin (ribavirin-PRINT-CFI and ribavirin-PRINT-IP) were developed for efficient delivery to the lung and to minimize bystander exposure. Ribavirin-PRINT-CFI was well tolerated in healthy participants after single dosing and ribavirin-PRINT-IP was well tolerated in healthy and COPD participants after single and repeat dosing. Ribavirin-PRINT-CFI was replaced with ribavirin-PRINT-IP since the latter formulation was found to have improved physicochemical properties and it had a higher ratio of active drug to excipient per unit dose. Ribavirin concentrations were measured in lung epithelial lining fluid in both healthy and COPD participants and achieved target concentrations. Both formulations were rapidly absorbed with approximately dose proportional pharmacokinetics in plasma. Exposure to bystanders was negligible based on both the plasma and airborne ribavirin concentrations with the ribavirin-PRINT-IP formulation. Thus, ribavirin-PRINT-IP allowed for an efficient and convenient delivery of ribavirin to the lungs while minimizing systemic exposure. Further clinical investigations would be required to demonstrate ribavirin-PRINT-IP antiviral characteristics and impact on COPD viral-induced exacerbations. (The clinical trials discussed in this study have been registered at ClinicalTrials.gov under identifiers NCT03243760 and NCT03235726.) |
format | Online Article Text |
id | pubmed-7179635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-71796352020-04-27 A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study Dumont, Etienne F. Oliver, Amanda J. Ioannou, Chris Billiard, Julia Dennison, Jeremy van den Berg, Frans Yang, Shuying Chandrasekaran, Vijayalakshmi Young, Graeme C. Lahiry, Anirban Starbuck, David C. Harrell, Andrew W. Georgiou, Alex Hopchet, Nathalie Gillies, Andy Baker, Stephen J. Antimicrob Agents Chemother Antiviral Agents Chronic obstructive pulmonary disease (COPD) is an inflammatory lung condition, causing progressive decline in lung function leading to premature death. Acute exacerbations in COPD patients are predominantly associated with respiratory viruses. Ribavirin is a generic broad-spectrum antiviral agent that could be used for treatment of viral respiratory infections in COPD. Using the Particle Replication In Nonwetting Templates (PRINT) technology, which produces dry-powder particles of uniform shape and size, two new inhaled formulations of ribavirin (ribavirin-PRINT-CFI and ribavirin-PRINT-IP) were developed for efficient delivery to the lung and to minimize bystander exposure. Ribavirin-PRINT-CFI was well tolerated in healthy participants after single dosing and ribavirin-PRINT-IP was well tolerated in healthy and COPD participants after single and repeat dosing. Ribavirin-PRINT-CFI was replaced with ribavirin-PRINT-IP since the latter formulation was found to have improved physicochemical properties and it had a higher ratio of active drug to excipient per unit dose. Ribavirin concentrations were measured in lung epithelial lining fluid in both healthy and COPD participants and achieved target concentrations. Both formulations were rapidly absorbed with approximately dose proportional pharmacokinetics in plasma. Exposure to bystanders was negligible based on both the plasma and airborne ribavirin concentrations with the ribavirin-PRINT-IP formulation. Thus, ribavirin-PRINT-IP allowed for an efficient and convenient delivery of ribavirin to the lungs while minimizing systemic exposure. Further clinical investigations would be required to demonstrate ribavirin-PRINT-IP antiviral characteristics and impact on COPD viral-induced exacerbations. (The clinical trials discussed in this study have been registered at ClinicalTrials.gov under identifiers NCT03243760 and NCT03235726.) American Society for Microbiology 2020-04-21 /pmc/articles/PMC7179635/ /pubmed/32071044 http://dx.doi.org/10.1128/AAC.02267-19 Text en Copyright © 2020 Dumont et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Antiviral Agents Dumont, Etienne F. Oliver, Amanda J. Ioannou, Chris Billiard, Julia Dennison, Jeremy van den Berg, Frans Yang, Shuying Chandrasekaran, Vijayalakshmi Young, Graeme C. Lahiry, Anirban Starbuck, David C. Harrell, Andrew W. Georgiou, Alex Hopchet, Nathalie Gillies, Andy Baker, Stephen J. A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study |
title | A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study |
title_full | A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study |
title_fullStr | A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study |
title_full_unstemmed | A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study |
title_short | A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study |
title_sort | novel inhaled dry-powder formulation of ribavirin allows for efficient lung delivery in healthy participants and those with chronic obstructive pulmonary disease in a phase 1 study |
topic | Antiviral Agents |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179635/ https://www.ncbi.nlm.nih.gov/pubmed/32071044 http://dx.doi.org/10.1128/AAC.02267-19 |
work_keys_str_mv | AT dumontetiennef anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT oliveramandaj anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT ioannouchris anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT billiardjulia anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT dennisonjeremy anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT vandenbergfrans anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT yangshuying anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT chandrasekaranvijayalakshmi anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT younggraemec anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT lahiryanirban anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT starbuckdavidc anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT harrellandreww anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT georgioualex anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT hopchetnathalie anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT gilliesandy anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT bakerstephenj anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT dumontetiennef novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT oliveramandaj novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT ioannouchris novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT billiardjulia novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT dennisonjeremy novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT vandenbergfrans novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT yangshuying novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT chandrasekaranvijayalakshmi novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT younggraemec novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT lahiryanirban novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT starbuckdavidc novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT harrellandreww novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT georgioualex novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT hopchetnathalie novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT gilliesandy novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study AT bakerstephenj novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study |